[ad_1]
This year’s rally for technology stocks hasn’t been broad-based. Analysts see opportunities among some of the software companies that have been left behind.
[ad_2]
Source link
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March...